N-Terminal pro-Brain Natriuretic Peptide (NT-proBNP)
Kit Name: Joinstar N-Terminal pro-Brain Natriuretic Peptide Detection Kit
Method: Fluorescence dry quantitative immunoassay
Assay measuring range: 30 pg/mL~3,5000 pg/mL
Incubation time: 18min
Sample: Human plasma (EDTA) and whole blood (EDTA)
Reference range:
|
Age groups |
Reference range |
|
<75 years old |
<125.0 pg/mL |
|
≥75 years old |
<450.0 pg/mL |
Storage and Stability:
✭Detection Buffer is stable for 12 months at 2°C ~8°C.
✭Sealed Test Device is stable for 12 months at 4°C～30°C.
•N-terminal pro B-type natriuretic peptide (NT-proBNP) is an inactive peptide released along with the active peptide hormone BNP when the walls of the heart are stretched or there is pressure overload on the heart by fluid overload.
•BNP then acts on the kidneys causing fluid and sodium loss in the urine and mild vasodilation so releasing the pressure.
•In heart failure the heart cannot pump strongly enough for the body’s requirements, the heart walls are stretched, and fluid starts to accumulate causing back pressure and hence more BNP to be released.
•NT-proBNP is released into the circulation in equal amounts to the active hormone but is significantly more stable and hence forms a good marker of BNP output.
•Assays for BNP and NT-proBNP have been increasingly used to establish the presence and severity of heart failure (HF).
•The level of NT-proBNP in patients with acute heart failure is significantly higher than that in patients with other causes of dyspnoea and is the independent predictor of heart failure in patients with acute dyspnoea.
•NT-proBNP has good diagnostic and prognostic value for acute heart failure. It can improve the accuracy of diagnosis, reduce the time of diagnosis and help to determine the prognosis.
Figure 2. Structure of BNP and NT-proBNP.
Figure 1. Structure of brain natriutetic peptide and its activation site.
•《2013 ACCF/AHA Guideline for the Management of Heart Failure》
✭In ambulatory patients with dyspnea, measurement of BNP or NT-proBNP is useful to support clinical decision making regarding the diagnosis of HF, especially in the setting of clinical uncertainty.
✭Measurement of BNP or NT-proBNP is useful for establishing prognosis or disease severity in chronic HF.
✭BNP- or NT-proBNP–guided HF therapy can be useful to achieve optimal dosing of GDMT in select clinically euvolemic patients followed in a well-structured HF disease management program.
✭Measurement of BNP or NT-proBNP is useful to support clinical judgment for the diagnosis of acutely decompensated HF, especially in the setting of uncertainty for the diagnosis.
✭Measurement of BNP or NT-proBNP and/or cardiac troponin is useful for establishing prognosis or disease severity in acutely decompensated HF.
•《2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure》
✭For patients at risk of developing HF, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset HF.
✭Measurement of BNP or NT-proBNP is useful for establishing prognosis or disease severity in chronic HF.
✭Measurement of baseline levels of natriuretic peptide biomarkers and/or cardiac troponin on admission to the hospital is useful to establish a prognosis in acutely decompensated HF.
✭During a HF hospitalization, a predischarge natriuretic peptide level can be useful to establish a postdischarge prognosis.
•Screening for heart failure
•Diagnosis of heart failure
•Risk stratification for heart failure
•Distinguish between cardiogenic and non-cardiogenic dyspnea
•Assessment of the severity and prognosis of heart failure
